| __timestamp | Gilead Sciences, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 15746000 |
| Thursday, January 1, 2015 | 3426000000 | 13392000 |
| Friday, January 1, 2016 | 3398000000 | 9290000 |
| Sunday, January 1, 2017 | 3878000000 | 7672000 |
| Monday, January 1, 2018 | 4056000000 | 15293000 |
| Tuesday, January 1, 2019 | 4381000000 | 22648000 |
| Wednesday, January 1, 2020 | 5151000000 | 21864000 |
| Friday, January 1, 2021 | 5246000000 | 37318000 |
| Saturday, January 1, 2022 | 5673000000 | 48130000 |
| Sunday, January 1, 2023 | 6090000000 | 108146000 |
| Monday, January 1, 2024 | 6091000000 |
Data in motion
In the ever-evolving landscape of biotechnology, understanding the financial health of companies is crucial. Selling, General, and Administrative (SG&A) expenses offer a window into a company's operational efficiency. From 2014 to 2023, Gilead Sciences, Inc. and Madrigal Pharmaceuticals, Inc. have shown contrasting trajectories in their SG&A costs.
Gilead Sciences, a titan in the biotech industry, has seen its SG&A expenses grow by over 100% from 2014 to 2023, peaking at approximately $6 billion. This reflects its expansive operations and strategic investments. In contrast, Madrigal Pharmaceuticals, a smaller player, has experienced a staggering 587% increase in SG&A expenses, reaching over $108 million in 2023. This surge underscores its aggressive growth strategy and market penetration efforts.
These trends highlight the dynamic nature of the biotech sector, where strategic spending can be a harbinger of future growth and innovation.
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?